Tankyrase-targeted therapeutics: Expanding opportunities in the PARP family

Nature Reviews Drug Discovery

Volumn 11, Issue 12, 2012, Pages 923-936

  Riffell, Jenna L ^a   Lord, Christopher J ^a   Ashworth, Alan ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 AMINOBENZAMIDE; AXIN; BETA CATENIN; BMN 673; CEP 8983; CEP 9722; FLAVONE; GLUCOSE TRANSPORTER 4; INIPARIB; JW 55; N (5,6 DIHYDRO 6 OXO 2 PHENANTHRIDINYL) 2 DIMETHYLAMINOACETAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 2; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NIRAPARIB; OLAPARIB; RUCAPARIB; TANKYRASE; TANKYRASE 1; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VELIPARIB; XAV 939;

BREAST CANCER; CANCER INHIBITION; DNA DAMAGE; DNA REPAIR; DRUG SCREENING; DRUG STRUCTURE; ENZYME PHOSPHORYLATION; ENZYME STRUCTURE; ENZYME SUBSTRATE COMPLEX; GLUCOSE TRANSPORT; HOMOLOGOUS RECOMBINATION; HUMAN; IC 50; MITOSIS; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FUNCTION; REVIEW; TELOMERE; TRIPLE NEGATIVE BREAST CANCER; WNT SIGNALING PATHWAY;

ANIMALS; BETA CATENIN; DRUG DISCOVERY; ENZYME INHIBITORS; GLUCOSE; HUMANS; MITOSIS; PHOSPHORYLATION; TANKYRASES; TELOMERE; WNT SIGNALING PATHWAY;

EID: 84870855799     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd3868     Document Type: Review

References (107)

1. Durkacz, B. W., Omidiji, O., Gray, D. A. & Shall, S. (ADP-ribose)n participates in DNA excision repair. Nature 283, 593-596 (1980).
2. Durkacz, B. W., Shall, S. & Irwin, J. The effect of inhibition of (ADP-ribose)n biosynthesis on DNA repair assayed by the nucleoid technique. Eur. J. Biochem. 121, 65-69 (1981).
3. Rouleau, M., Patel, A., Hendzel, M. J., Kaufmann, S. H. & Poirier, G. G. PARP inhibition: PARP1 and beyond. Nature Rev. Cancer 10, 293-301 (2010).
4. Purnell, M. R. & Whish, W. J. Novel inhibitors of poly(ADP-ribose) synthetase. Biochem. J. 185, 775-777 (1980).
5. Durkacz, B. W., Irwin, J. & Shall, S. Inhibition of (ADP-ribose)n biosynthesis retards DNA repair but does not inhibit DNA repair synthesis. Biochem. Biophys. Res. Commun. 101, 1433-1441 (1981).
6. Wahlberg, E. et al. Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors. Nature Biotech. 30, 283-288 (2012).
7. Huang, S. M. et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 461, 614-620 (2009).
8. Smith, S., Giriat, I., Schmitt, A. & de Lange, T. Tankyrase, a poly(ADP-ribose) polymerase at human telomeres. Science 282, 1484-1487 (1998).
9. Hsiao, S. J. & Smith, S. Tankyrase function at telomeres, spindle poles, and beyond. Biochimie 90, 83-92 (2008).
10. Kaminker, P. G. et al. TANK2, a new TRF1 associated poly(ADP-ribose) polymerase, causes rapid induction of cell death upon overexpression. J. Biol. Chem. 276, 35891-35899 (2001).
11. Chiang, Y. J. et al. Tankyrase 1 and tankyrase 2 are essential but redundant for mouse embryonic development. PLoS ONE 3, e2639 (2008).
12. Guettler, S. et al. Structural basis and sequence rules for substrate recognition by tankyrase explain the basis for cherubism disease. Cell 147, 1340-1354 (2011).
13. Seimiya, H., Muramatsu, Y., Smith, S. & Tsuruo, T. Functional subdomain in the ankyrin domain of tankyrase 1 required for poly(ADP-ribosyl) ation of TRF1 and telomere elongation. Mol. Cell. Biol. 24, 1944-1955 (2004).
14. Morrone, S., Cheng, Z., Moon, R. T., Cong, F. & Xu, W. Crystal structure of a tankyrase-axin complex and its implications for axin turnover and tankyrase substrate recruitment. Proc. Natl Acad. Sci. USA 109, 1500-1505 (2012).
15. Seimiya, H. & Smith, S. The telomeric poly(ADP-ribose) polymerase, tankyrase 1, contains multiple binding sites for telomeric repeat binding factor 1 (TRF1) and a novel acceptor, 182 kDa tankyrase-binding protein (TAB182). J. Biol. Chem. 277, 14116-14126 (2002).
16. Chi, N. W. & Lodish, H. F. Tankyrase is a Golgi-associated mitogen-activated protein kinase substrate that interacts with IRAP in GLUT4 vesicles. J. Biol. Chem. 275, 38437-38444 (2000).
17. Yeh, T. Y., Sbodio, J. I. & Chi, N. W. Mitotic phosphorylation of tankyrase, a PARP that promotes spindle assembly, by GSK3. Biochem. Biophys. Res. Commun. 350, 574-579 (2006).
18. Ha, G. H. et al. Tankyrase 1 function at telomeres and during mitosis is regulated by Polo-like kinase 1- mediated phosphorylation. Cell Death Differ. 19, 321-332 (2012).
19. Yu, M. et al. PARP 10, a novel Myc-interacting protein with poly(ADP-ribose) polymerase activity, inhibits transformation. Oncogene 24, 1982-1993 (2005).
20. Casas-Selves, M. et al. Tankyrase and the canonical Wnt pathway protect lung cancer cells from EGFR inhibition. Cancer Res. 72, 4154-4164 (2012).
21. d'Adda di Fagagna, F. et al. A DNA damage checkpoint response in telomere-initiated senescence. Nature 426, 194-198 (2003).
22. Kim, N. W. et al. Specific association of human telomerase activity with immortal cells and cancer. Science 266, 2011-2015 (1994).
23. Buseman, C. M., Wright, W. E. & Shay, J. W. Is telomerase a viable target in cancer? Mutat. Res. 730, 90-97 (2012).
24. Smogorzewska, A. & de Lange, T. Regulation of telomerase by telomeric proteins. Annu. Rev. Biochem. 73, 177-208 (2004).
25. Palm, W. & de Lange, T. How shelterin protects mammalian telomeres. Annu. Rev. Genet. 42, 301-334 (2008).
26. Smith, S. & de Lange, T. Tankyrase promotes telomere elongation in human cells. Curr. Biol. 10, 1299-1302 (2000).
27. Lee, T. H., Perrem, K., Harper, J. W., Lu, K. P. & Zhou, X. Z. The F box protein FBX4 targets PIN2/TRF1 for ubiquitin-mediated degradation and regulates telomere maintenance. J. Biol. Chem. 281, 759-768 (2006).
28. Her, Y. R. & Chung, I. K. Ubiquitin ligase RLIM modulates telomere length homeostasis through a proteolysis of TRF1. J. Biol. Chem. 284, 8557-8566 (2009).
29. Bailey, S. M. et al. The kinase activity of DNA PK is required to protect mammalian telomeres. DNA Repair 3, 225-233 (2004).
30. Williams, E. S. et al. Telomere dysfunction and DNA-PKcs deficiency: characterization and consequence. Cancer Res. 69, 2100-2107 (2009).
31. Dregalla, R. C. et al. Regulatory roles of tankyrase 1 at telomeres and in DNA repair: suppression of T SCE and stabilization of DNA-PKcs. Aging 2, 691-708 (2010).
32. Donigian, J. R. & de Lange, T. The role of the poly(ADP-ribose) polymerase tankyrase1 in telomere length control by the TRF1 component of the shelterin complex. J. Biol. Chem. 282, 22662-22667 (2007).
33. Cook, B. D., Dynek, J. N., Chang, W., Shostak, G. & Smith, S. Role for the related poly(ADP-ribose) polymerases tankyrase 1 and 2 at human telomeres. Mol. Cell. Biol. 22, 332-342 (2002).
34. Seimiya, H., Muramatsu, Y., Ohishi, T. & Tsuruo, T. Tankyrase 1 as a target for telomere-directed molecular cancer therapeutics. Cancer Cell 7, 25-37 (2005).
35. Cerone, M. A., Burgess, D. J., Naceur-Lombardelli, C., Lord, C. J. & Ashworth, A. High-throughput RNAi screening reveals novel regulators of telomerase. Cancer Res. 71, 3328-3340 (2011).
36. Clevers, H. & Nusse, R. Wnt/β-catenin signaling and disease. Cell 149, 1192-1205 (2012).
37. He, X. et al. A member of the Frizzled protein family mediating axis induction by Wnt 5A. Science 275, 1652-1654 (1997).
38. Tamai, K. et al. LDL-receptor-related proteins in Wnt signal transduction. Nature 407, 530-535 (2000).
39. Polakis, P. Wnt signaling and cancer. Genes Dev. 14, 1837-1851 (2000).
40. Hart, M. J., de los Santos, R., Albert, I. N., Rubinfeld, B. & Polakis, P. Downregulation of β-catenin by human axin and its association with the APC tumor suppressor, β-catenin and GSK3β. Curr. Biol. 8, 573-581 (1998).
41. Li, V. S. et al. Wnt signaling through inhibition of β-catenin degradation in an intact Axin1 complex. Cell 149, 1245-1256 (2012).
42. Morin, P. J. et al. Activation of β-catenin-Tcf signaling in colon cancer by mutations in β-catenin or APC. Science 275, 1787-1790 (1997).
43. Zhang, Y. et al. RNF146 is a poly(ADP-ribose)-directed E3 ligase that regulates axin degradation and Wnt signalling. Nature Cell Biol. 13, 623-629 (2011).
44. Callow, M. G. et al. Ubiquitin ligase RNF146 regulates tankyrase and Axin to promote Wnt signaling. PLoS ONE 6, e22595 (2011).
45. Zhou, Z. D., Chan, C. H., Xiao, Z. C. & Tan, E. K. Ring finger protein 146/iduna is a poly(ADP-ribose) polymer binding and PARsylation dependent E3 ubiquitin ligase. Cell Adh. Migr. 5, 463-471 (2011).
46. Kang, H. C. et al. Iduna is a poly(ADP-ribose) (PAR)- dependent E3 ubiquitin ligase that regulates DNA damage. Proc. Natl Acad. Sci. USA 108, 14103-14108 (2011).
47. Tenbaum, S. P. et al. β-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer. Nature Med. 18, 892-901 (2012).
48. Wang, H., Hao, J. & Hong, C. C. Cardiac induction of embryonic stem cells by a small molecule inhibitor of Wnt/β-catenin signaling. ACS Chem. Biol. 6, 192-197 (2011).
49. Ulsamer, A. et al. Axin pathway activity regulates in vivo pY654-β-catenin accumulation and pulmonary fibrosis. J. Biol. Chem. 287, 5164-5172 (2012).
50. Fancy, S. P. et al. Axin2 as regulatory and therapeutic target in newborn brain injury and remyelination. Nature Neurosci. 14, 1009-1016 (2011).
51. Hsiao, S. J. & Smith, S. Sister telomeres rendered dysfunctional by persistent cohesion are fused by NHEJ. J. Cell Biol. 184, 515-526 (2009).
52. Dynek, J. N. & Smith, S. Resolution of sister telomere association is required for progression through mitosis. Science 304, 97-100 (2004).
53. Chang, W., Dynek, J. N. & Smith, S. NuMA is a major acceptor of poly(ADP-ribosyl)ation by tankyrase 1 in mitosis. Biochem. J. 391, 177-184 (2005).
54. Chang, P., Coughlin, M. & Mitchison, T. J. Tankyrase 1 polymerization of poly(ADP-ribose) is required for spindle structure and function. Nature Cell Biol. 7, 1133-1139 (2005).
55. Boehler, C. et al. Poly(ADP-ribose) polymerase 3 (PARP3), a newcomer in cellular response to DNA damage and mitotic progression. Proc. Natl Acad. Sci. USA 108, 2783-2788 (2011).
56. Chou, H. Y., Chou, H. T. & Lee, S. C. CDK-dependent activation of poly(ADP-ribose) polymerase member 10 (PARP10). J. Biol. Chem. 281, 15201-15207 (2006).
57. Yeh, T. Y., Sbodio, J. I., Tsun, Z. Y., Luo, B. & Chi, N. W. Insulin-stimulated exocytosis of GLUT4 is enhanced by IRAP and its partner tankyrase. Biochem. J. 402, 279-290 (2007).
58. Guo, H. L. et al. The Axin/TNKS complex interacts with KIF3A and is required for insulin-stimulated GLUT4 translocation. Cell Res. 22, 1246-1257 (2012).
59. Levaot, N. et al. Loss of tankyrase-mediated destruction of 3BP2 is the underlying pathogenic mechanism of cherubism. Cell 147, 1324-1339 (2011).
60. Li, Z. et al. Herpes simplex virus requires poly(ADP-ribose) polymerase activity for efficient replication and induces extracellular signal-related kinase-dependent phosphorylation and ICP0 dependent nuclear localization of tankyrase 1. J. Virol. 86, 492-503 (2012).
61. McCabe, N. et al. Targeting tankyrase 1 as a therapeutic strategy for BRCA-associated cancer. Oncogene 28, 1465-1470 (2009).
62. Daniels, M. J., Wang, Y., Lee, M. & Venkitaraman, A. R. Abnormal cytokinesis in cells deficient in the breast cancer susceptibility protein BRCA2. Science 306, 876-879 (2004).
63. Chen, B. et al. Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer. Nature Chem. Biol. 5, 100-107 (2009).
64. Waaler, J. et al. A novel tankyrase inhibitor decreases canonical Wnt signaling in colon carcinoma cells and reduces tumor growth in conditional APC mutant mice. Cancer Res. 72, 2822-2832 (2012).
65. Yashiroda, Y. et al. A novel yeast cell-based screen identifies flavone as a tankyrase inhibitor. Biochem. Biophys. Res. Commun. 394, 569-573 (2010).
66. Narwal, M., Venkannagari, H. & Lehtio, L. Structural basis of selective inhibition of human tankyrases. J. Med. Chem. 55, 1360-1367 (2012).
67. Gunaydin, H., Gu, Y. & Huang, X. Novel binding mode of a potent and selective tankyrase inhibitor. PLoS ONE 7, e33740 (2012).
68. Shultz, M. D. et al. [1,2,4]triazol-3 ylsulfanylmethyl)- 3 phenyl-[1,2,4]oxadiazoles: antagonists of the Wnt pathway that inhibit tankyrases 1 and 2 via novel adenosine pocket binding. J. Med. Chem. 55, 1127-1136 (2012).
69. Kirby, C. A., Cheung, A., Fazal, A., Shultz, M. D. & Stams, T. Structure of human tankyrase 1 in complex with small-molecule inhibitors PJ34 and XAV939. Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun. 68, 115-118 (2012).
70. Zaremba, T. & Curtin, N. J. PARP inhibitor development for systemic cancer targeting. Anticancer Agents Med. Chem. 7, 515-523 (2007).
71. Muramatsu, Y., Ohishi, T., Sakamoto, M., Tsuruo, T. & Seimiya, H. Cross-species difference in telomeric function of tankyrase 1. Cancer Sci. 98, 850-857 (2007).
72. Lord, C. J. & Ashworth, A. Biology-driven cancer drug development: back to the future. BMC Biol. 8, 38 (2010).
73. Lievre, A. et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 66, 3992-3995 (2006).
74. Kleine, H. et al. Substrate-assisted catalysis by PARP10 limits its activity to mono-ADP-ribosylation. Mol. Cell 32, 57-69 (2008).
75. Hottiger, M. O., Hassa, P. O., Luscher, B., Schuler, H. & Koch-Nolte, F. Toward a unified nomenclature for mammalian ADP-ribosyltransferases. Trends Biochem. Sci. 35, 208-219 (2010).
76. Manke, I. A., Lowery, D. M., Nguyen, A. & Yaffe, M. B. BRCT repeats as phosphopeptide-binding modules involved in protein targeting. Science 302, 636-639 (2003).
77. Langelier, M. F., Planck, J. L., Roy, S. & Pascal, J. M. Structural basis for DNA damage-dependent poly(ADP-ribosyl)ation by human PARP 1. Science 336, 728-732 (2012).
78. Fisher, A. E., Hochegger, H., Takeda, S. & Caldecott, K. W. Poly(ADP-ribose) polymerase 1 accelerates single-strand break repair in concert with poly(ADP-ribose) glycohydrolase. Mol. Cell. Biol. 27, 5597-5605 (2007).
79. Mortusewicz, O., Ame, J. C., Schreiber, V. & Leonhardt, H. Feedback-regulated poly(ADP-ribosyl)ation by PARP 1 is required for rapid response to DNA damage in living cells. Nucleic Acids Res. 35, 7665-7675 (2007).
80. Rulten, S. L. et al. PARP 3 and APLF function together to accelerate nonhomologous end-joining. Mol. Cell 41, 33-45 (2011).
81. Kickhoefer, V. A. et al. The 193 kD vault protein, VPARP, is a novel poly(ADP-ribose) polymerase. J. Cell Biol. 146, 917-928 (1999).
82. Lara, P. C., Pruschy, M., Zimmermann, M. & Henriquez-Hernandez, L. A. MVP and vaults: a role in the radiation response. Radiat. Oncol. 6, 148 (2011).
83. Welsby, I., Hutin, D. & Leo, O. Complex roles of members of the ADP-ribosyl transferase super family in immune defences: looking beyond PARP1. Biochem. Pharmacol. 84, 11-20 (2012).
84. Ogata, N., Ueda, K., Kawaichi, M. & Hayaishi, O. Poly(ADP-ribose) synthetase, a main acceptor of poly(ADP-ribose) in isolated nuclei. J. Biol. Chem. 256, 4135-4137 (1981).
85. Dantzer, F. et al. Involvement of poly(ADP-ribose) polymerase in base excision repair. Biochimie 81, 69-75 (1999).
86. David, S. S., O'Shea, V. L. & Kundu, S. Base-excision repair of oxidative DNA damage. Nature 447, 941-950 (2007).
87. Delaney, C. A. et al. Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines. Clin. Cancer Res. 6, 2860-2867 (2000).
88. Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917-921 (2005).
89. Bryant, H. E. et al. Specific killing of BRCA2 deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913-917 (2005).
90. Chen, J. J., Silver, D., Cantor, S., Livingston, D. M. & Scully, R. BRCA1, BRCA2, and Rad51 operate in a common DNA damage response pathway. Cancer Res. 59, 1752s-1756s (1999).
91. Fong, P. C. et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361, 123-134 (2009).
92. De Vos, M., Schreiber, V. & Dantzer, F. The diverse roles and clinical relevance of PARPs in DNA damage repair: current state of the art. Biochem. Pharmacol. 84, 137-146 (2012).
93. Brenner, J. C. et al. Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell 19, 664-678 (2011).
94. Erener, S. et al. Inflammasome-activated caspase 7 cleaves PARP1 to enhance the expression of a subset of NF κB target genes. Mol. Cell 46, 200-211 (2012).
95. Mendeleyev, J., Kirsten, E., Hakam, A., Buki, K. G. & Kun, E. Potential chemotherapeutic activity of 4 iodo 3 nitrobenzamide. Metabolic reduction to the 3 nitroso derivative and induction of cell death in tumor cells in culture. Biochem. Pharmacol. 50, 705-714 (1995).
96. Patel, A. G., De Lorenzo, S. B., Flatten, K. S., Poirier, G. G. & Kaufmann, S. H. Failure of iniparib to inhibit poly(ADP-ribose) polymerase in vitro. Clin. Cancer Res. 18, 1655-1662 (2012).
97. Davidovic, L., Vodenicharov, M., Affar, E. B. & Poirier, G. G. Importance of poly(ADP-ribose) glycohydrolase in the control of poly(ADP-ribose) metabolism. Exp. Cell Res. 268, 7-13 (2001).
98. Huang, H. Y. et al. Role of poly(ADP-ribose) glycohydrolase in the regulation of cell fate in response to benzo(a)pyrene. Exp. Cell Res. 318, 682-690 (2012).
99. Zhou, Y., Feng, X. & Koh, D. W. Activation of cell death mediated by apoptosis-inducing factor due to the absence of poly(ADP-ribose) glycohydrolase. Biochemistry 50, 2850-2859 (2011).
100. Mortusewicz, O., Fouquerel, E., Ame, J. C., Leonhardt, H. & Schreiber, V. PARG is recruited to DNA damage sites through poly(ADP-ribose)- and PCNA-dependent mechanisms. Nucleic Acids Res. 39, 5045-5056 (2011).
101. Ame, J. C. et al. Radiation-induced mitotic catastrophe in PARG-deficient cells. J. Cell Sci. 122, 1990-2002 (2009).
102. Fathers, C., Drayton, R. M., Solovieva, S. & Bryant, H. E. Inhibition of poly(ADP-ribose) glycohydrolase (PARG) specifically kills BRCA2 deficient tumor cells. Cell Cycle 11, 990-997 (2012).
103. Finch, K. E., Knezevic, C. E., Nottbohm, A. C., Partlow, K. C. & Hergenrother, P. J. Selective small molecule inhibition of poly(ADP-ribose) glycohydrolase (PARG). ACS Chem. Biol. 7, 563-570 (2012).
104. Bisht, K. K. et al. GDP-mannose-4,6-dehydratase is a cytosolic partner of tankyrase 1 that inhibits its poly(ADP-ribose) polymerase activity. Mol. Cell. Biol. 32, 3044-3053 (2012).
105. Menear, K. A. et al. 4-[3-(4 cyclopropanecarbonylpiperazine-1 carbonyl)-4 fluorobenzyl]- 2H phthalazin-1 one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase 1. J. Med. Chem. 51, 6581-6591 (2008).
106. Jones, P. et al. Discovery of 2-{4-[(3S)-piperidin-3 yl] phenyl}-2H indazole-7 carboxamide (MK 4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA 1 and -2 mutant tumors. J. Med. Chem. 52, 7170-7185 (2009).
107. Miknyoczki, S. et al. The selective poly(ADP-ribose) polymerase 1(2) inhibitor, CEP 8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity. Mol. Cancer Ther. 6, 2290-2302 (2007).